Adenosine A2A Antagonists in Parkinsons Disease: Whats Next

Current Neurology and Neuroscience Reports, 06/08/2012

The safety and efficacy of this class of compounds continues to be defined and future studies should focus on non–motor symptoms, dyskinesias, and neuroprotection.

Print Article Summary